Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)
China
· Delayed Price · Currency is CNY 83.01
+0.02 (0.02%)
Feb 28, 2025, 2:44 PM CST
Xiamen Amoytop Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2016 |
| Operating Revenue | 2,817 | 2,093 | 1,517 | 1,123 | 789.39 | Upgrade
|
| Other Revenue | - | 7.74 | 10 | 9.51 | 4.54 | Upgrade
|
| Revenue | 2,817 | 2,100 | 1,527 | 1,132 | 793.93 | Upgrade
|
| Revenue Growth (YoY) | 34.13% | 37.55% | 34.86% | 42.61% | 8.81% | Upgrade
|
| Cost of Revenue | - | 143.16 | 171.01 | 126.99 | 85.65 | Upgrade
|
| Gross Profit | 2,817 | 1,957 | 1,356 | 1,005 | 708.29 | Upgrade
|
| Selling, General & Admin | - | 1,057 | 841.02 | 700.65 | 503.55 | Upgrade
|
| Research & Development | - | 228.52 | 148.58 | 79.74 | 74.23 | Upgrade
|
| Other Operating Expenses | 1,846 | 10.95 | 7.64 | 5.55 | 3.83 | Upgrade
|
| Operating Expenses | 1,846 | 1,297 | 995.83 | 783.6 | 581.42 | Upgrade
|
| Operating Income | 970.74 | 659.88 | 360.06 | 221.64 | 126.86 | Upgrade
|
| Interest Expense | - | -0.51 | -0.62 | -1.07 | -2.46 | Upgrade
|
| Interest & Investment Income | - | 10.17 | 8.09 | 7.84 | 3.67 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -1.03 | 0.48 | -0.47 | -0.95 | Upgrade
|
| Other Non Operating Income (Expenses) | -39.71 | -0.39 | -0.25 | -0.24 | 0.39 | Upgrade
|
| EBT Excluding Unusual Items | 931.03 | 668.13 | 367.77 | 227.69 | 127.51 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 2.65 | 0.4 | 1.8 | 3.96 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.87 | 0.03 | -1.8 | -1.13 | Upgrade
|
| Asset Writedown | - | -12.76 | - | - | - | Upgrade
|
| Other Unusual Items | - | -16.49 | -12.27 | -12.4 | 8.73 | Upgrade
|
| Pretax Income | 931.03 | 640.65 | 355.93 | 215.29 | 139.07 | Upgrade
|
| Income Tax Expense | 103.42 | 85.21 | 68.91 | 34.09 | 22.5 | Upgrade
|
| Net Income | 827.6 | 555.45 | 287.02 | 181.2 | 116.57 | Upgrade
|
| Net Income to Common | 827.6 | 555.45 | 287.02 | 181.2 | 116.57 | Upgrade
|
| Net Income Growth | 49.00% | 93.52% | 58.40% | 55.44% | 81.31% | Upgrade
|
| Shares Outstanding (Basic) | 408 | 405 | 404 | 403 | 402 | Upgrade
|
| Shares Outstanding (Diluted) | 408 | 405 | 404 | 403 | 402 | Upgrade
|
| Shares Change (YoY) | 0.55% | 0.29% | 0.39% | 0.18% | 12.54% | Upgrade
|
| EPS (Basic) | 2.03 | 1.37 | 0.71 | 0.45 | 0.29 | Upgrade
|
| EPS (Diluted) | 2.03 | 1.37 | 0.71 | 0.45 | 0.29 | Upgrade
|
| EPS Growth | 48.18% | 92.96% | 57.78% | 55.17% | 61.11% | Upgrade
|
| Free Cash Flow | - | 223.64 | 143.99 | 43.85 | -26.2 | Upgrade
|
| Free Cash Flow Per Share | - | 0.55 | 0.36 | 0.11 | -0.07 | Upgrade
|
| Dividend Per Share | - | 0.410 | 0.213 | 0.100 | 0.050 | Upgrade
|
| Dividend Growth | - | 92.49% | 113.00% | 100.00% | 100.00% | Upgrade
|
| Gross Margin | 100.00% | 93.18% | 88.80% | 88.78% | 89.21% | Upgrade
|
| Operating Margin | 34.46% | 31.42% | 23.58% | 19.58% | 15.98% | Upgrade
|
| Profit Margin | 29.38% | 26.45% | 18.80% | 16.00% | 14.68% | Upgrade
|
| Free Cash Flow Margin | - | 10.65% | 9.43% | 3.87% | -3.30% | Upgrade
|
| EBITDA | 1,023 | 712.11 | 403.23 | 260.33 | 165.03 | Upgrade
|
| EBITDA Margin | 36.31% | 33.90% | 26.41% | 22.99% | 20.79% | Upgrade
|
| D&A For EBITDA | 52.23 | 52.23 | 43.17 | 38.69 | 38.17 | Upgrade
|
| EBIT | 970.74 | 659.88 | 360.06 | 221.64 | 126.86 | Upgrade
|
| EBIT Margin | 34.46% | 31.42% | 23.58% | 19.58% | 15.98% | Upgrade
|
| Effective Tax Rate | 11.11% | 13.30% | 19.36% | 15.83% | 16.18% | Upgrade
|
| Revenue as Reported | - | 2,100 | 1,527 | 1,132 | 793.93 | Upgrade
|
| Advertising Expenses | - | 4.94 | 2.94 | 5.48 | 6.38 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.